stockrowWhat it does
Protagonist Therapeutics discovers and develops medicines for inflammatory and immune diseases, blood disorders, and metabolic diseases. Its technology platform is used to discover drug candidates, including peptides: molecules that can act on specific biological targets. Dinesh V. Patel is its president and chief executive officer.
Its partnered psoriasis medicine, Icotyde, is an oral peptide that blocks the IL-23 receptor, which is involved in inflammation. Protagonist and scientists at Johnson & Johnson jointly discovered it; Janssen Biotech, a Johnson & Johnson company, holds the license and is responsible for later-stage development. In 2025, Janssen submitted applications seeking approval in the United States and Europe for moderate-to-severe plaque psoriasis.
Protagonist also discovered rusfertide, an injectable medicine designed to mimic the hormone hepcidin and regulate red blood cell production in polycythemia vera, a rare blood disorder. Takeda is its development and commercialization partner. It was reported on 27 October 2026 that rusfertide, marketed as MIMRYLO, was approved in the United States to treat erythrocytosis in adults with polycythemia vera.
Other programs include PN-881, an oral candidate for inflammatory diseases; PN-477 and PN-458, candidates for obesity; and PN-8047, an oral candidate for polycythemia vera. These programs are at earlier stages of development.
How it makes money
Protagonist operates in one reportable segment and has historically funded its operations primarily through collaboration payments and proceeds from sales of common stock. Collaboration agreements can provide upfront payments, payments when development or sales milestones are met, and royalties on product sales. Future commercial milestones and royalties depend on approval and successful launch of the relevant products.
FY2025 single reportable segment revenue was $46.0 million; it was reported on 29 October 2026 that Q3 2026 revenue was expected to be $267.01 million. The quarterly figure is an expectation, not a reported quarterly result.
For Icotyde, Janssen is responsible for development after the initial Phase 1 study. Protagonist is eligible for up to $630.0 million in future development and sales milestones and royalties ranging from 6% to 10% of worldwide net sales. Royalties would depend on sales rather than a fixed recurring payment. Protagonist has earned $337.5 million in milestones under the agreement.
The rusfertide agreement with Takeda provides for equal sharing of U.S. profits and losses and royalties of 10% to 17% on net sales outside the United States. As of the end of 2025, Protagonist expected to exercise its right to leave the U.S. profit-and-loss sharing arrangement in the second quarter of 2026. Under that option, Takeda would hold an exclusive worldwide license and Protagonist would receive royalties of 14% to 29% on worldwide net sales, along with eligibility for specified milestone and opt-out payments.
It was subsequently reported on 27 October 2026 that Protagonist had licensed rusfertide to Takeda for worldwide commercialization. Protagonist also continues to develop wholly owned candidates, including PN-881 and its obesity programs.
| Segment | Revenue, FY2025 | Share | Change on the year |
|---|---|---|---|
| Single reportable segment | $46.0 million | 100.0% | −89.4% |
Customers and how it sells
Protagonist’s collaboration partners include Janssen Biotech for Icotyde and Takeda for rusfertide. One customer accounted for 100.0% of revenue in FY2025; the available information does not identify that customer. Protagonist received a rusfertide development milestone from Takeda in September 2025.
The intended patients for Icotyde include people with moderate-to-severe plaque psoriasis. Rusfertide is directed at people with polycythemia vera, a blood disorder characterized by excess red blood cell production. Other candidates are being developed for inflammatory skin diseases and obesity. Protagonist does not currently have a marketing and sales organization.
The Icotyde agreement covers worldwide sales, and Janssen submitted applications for approval in the United States and Europe in 2025. The rusfertide agreement also covers worldwide development and commercialization, with its payment terms distinguishing U.S. profit sharing from royalties on sales outside the United States before any opt-out. The company describes patients in both the United States and Europe as potential recipients of polycythemia vera treatment.
| Segment | Revenue, FY2025 | Share | Change on the year |
|---|---|---|---|
| Single reportable segment | $46.0 million | 100.0% | −89.4% |
Suppliers and costs
Protagonist relies on contract manufacturers to make drug supplies that meet regulatory requirements. It does not have internal manufacturing capability and does not plan to develop that infrastructure; it expects to continue relying on outside manufacturers. No individual manufacturer or sole-source supplier is named in the available information.
Research and development and general and administrative costs have accounted for substantially all of the company’s cumulative net losses. Protagonist expects significant research and development and other expenses to continue as it advances clinical and preclinical programs. Development responsibilities also vary by partnership: Janssen is responsible for later development of Icotyde, while Protagonist remained primarily responsible for rusfertide clinical development through its application filing and for ongoing long-term extension studies.
The company ended fiscal 2025 with approximately $646.0 million in cash, cash equivalents and marketable securities.
- Revenue$46.0M
- Research and development−$159.3M
- Selling, general and administrative−$44.9M
- Operating income−$158.1M
Competitive position
Protagonist competes with established and emerging pharmaceutical and biotechnology companies, as well as research institutions. In inflammatory diseases, treatments include injectable medicines targeting IL-23 and IL-17 and oral alternatives such as Otezla and Sotyktu. Johnson & Johnson, Protagonist’s Icotyde partner, also sells the IL-23-pathway medicines Stelara and Tremfya.
In obesity, Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound are established treatments. Oral Wegovy launched in the United States in January 2026. Eli Lilly is also developing retatrutide, an injectable candidate targeting three receptors; Protagonist’s PN-477 targets the same three receptor types and is being developed in oral and injectable forms.
Protagonist’s proprietary platform was used to discover Icotyde and rusfertide. Its wholly owned PN-881 and obesity candidates also use the platform. Our reading: the platform provides a source of differentiation across several programs, but its protection as a competitive advantage remains uncertain while earlier candidates advance through testing.
The company seeks to protect its candidates and technologies with intellectual property, but notes that similar compounds may be developed outside its patent claims and that patents can be challenged. Our reading: intellectual property may support a moat, but its strength is uncertain because rights may not cover competing approaches or withstand challenges.
| Competitor | Where they compete | Threat (our reading) |
|---|---|---|
| Novo Nordisk | Obesity medicines, including injectable and oral Wegovy | High |
| Eli Lilly | Obesity medicines and multi-receptor candidates | High |
| Johnson & Johnson | IL-23 treatments for inflammatory diseases; also Icotyde partner | Medium |
Growth opportunities
Protagonist’s partnered medicines offer potential revenue through milestones and royalties if development, approval and commercial requirements are met. Janssen expected to launch Icotyde in the United States in 2026, subject to regulatory approval. Takeda expected a rusfertide launch in the second half of 2026, also subject to approval; it was later reported on 27 October 2026 that rusfertide was approved in the United States for erythrocytosis in adults with polycythemia vera.
The company is also developing wholly owned medicines. It expected to complete the Phase 1 study of PN-881 in mid-2026 and start a Phase 2 psoriasis study by the end of 2026. It anticipated starting Phase 1 studies of injectable and oral PN-477 in mid-2026 and the second half of 2026, respectively. PN-458 and PN-8047 were in studies intended to support applications to begin human trials.
Protagonist describes potential uses for its inflammatory candidates beyond psoriasis, including psoriatic arthritis and other immune-mediated diseases. It also sizes global psoriasis therapy sales at $25.4 billion in 2024 and expects them to exceed $39.0 billion by 2030. For obesity medicines, the company expects the global market to reach more than $120 billion by 2034. Those market estimates are not Protagonist revenue targets.
- $27.4MFY2021
- $26.6MFY2022
- $60.0MFY2023
- $434.4MFY2024
- $46.0MFY2025
Structural risks
- Development and approval: Protagonist depends on its candidates succeeding in clinical development. Regulators may disagree with trial design or data interpretation, or conclude that a candidate’s safety and efficacy have not been adequately demonstrated.
- Partners: The business would be adversely affected if Janssen did not continue developing or successfully commercialize Icotyde, or if Takeda did not elect to commercialize rusfertide. Commercial milestone and royalty receipts also depend on successful launches.
- Manufacturing: Protagonist relies on contract manufacturers and does not plan to build internal drug-supply manufacturing capability. Contractors must meet applicable manufacturing requirements for approval and supply.
- Commercialization and competition: Protagonist has no marketing and sales organization. Product uptake can depend on competing treatments, physician prescribing, patient acceptance, insurance coverage and reimbursement.
- Financing and costs: The company has incurred cumulative net losses and may incur significant losses in the future. It expects continuing expenses for research, clinical development and preclinical discovery.
- Intellectual property: Patent applications may not result in issued patents, and issued patents may be narrowed, invalidated or challenged. Other companies may develop similar or alternative technologies without infringing Protagonist’s rights.
Bottom line
Our reading
Our reading: Protagonist is a drug discovery and development business whose near-term commercial economics depend substantially on partnered medicines, milestones and royalties, while its wholly owned pipeline remains earlier in development. Its cash resources support ongoing work, but approval, commercialization, partner execution and continued development spending remain central exposures.